ArticleBiochemistry and biophysics reports2025
HMGB1 impairs nasal mucosa epithelial barrier function in allergic rhinitis by promoting BECN1-mediating autophagy.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The role of calcium homeostasis dysregulation in allergic rhinitis.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a potent proinflammatory cytokine, high mobility group box 1 (HMGB1) exacerbates nasal mucosal epithelial barrier dysfunction. This study elucidates the mechanistic role of HMGB1 in driving epithelial barrier impairment in allergic rhinitis (AR). HMGB1 knockdown in human nasal epithelial cells (hNEpiC) significantly reduced LC3B expression and other autophagy markers, indicating suppressed autophagic activity. Notably, HMGB1 deficiency conferred resistance to IL-4-induced barrier dysfunction, manifested by increased transepithelial electrical resistance (TEER), decreased FITC-dextran permeability, and upregulated tight junction protein expressions (ZO-1, Occludin, and Claudin-1). Mechanistically, luciferase reporter assays demonstrated HMGB1's capacity to activate the BECN1 promoter, establishing a transcriptional regulatory mechanism. Crucially, BECN1 silencing abolished both HMGB1-induced autophagy and subsequent epithelial barrier disruption. Our findings identify HMGB1 as a critical mediator of AR progression through BECN1-dependent autophagy activation, suggesting that targeting this axis may represent a novel therapeutic strategy for AR management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.